<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B9C3C494-3A9C-4866-8022-D79B29D2CD88"><gtr:id>B9C3C494-3A9C-4866-8022-D79B29D2CD88</gtr:id><gtr:firstName>Adriano</gtr:firstName><gtr:surname>Rossi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/670260BC-6C2F-4969-AC3A-605AC2879977"><gtr:id>670260BC-6C2F-4969-AC3A-605AC2879977</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Haslett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0F243FCD-57DA-48E3-9933-8193EA373C82"><gtr:id>0F243FCD-57DA-48E3-9933-8193EA373C82</gtr:id><gtr:firstName>Nik</gtr:firstName><gtr:surname>Hirani</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701740"><gtr:id>FD35A1CA-2D39-41A8-A111-7CFE1D182589</gtr:id><gtr:title>CDK INHIBITION THERAPY AND POTENTIAL FOR NOVEL IMAGING BIOMARKERS IN IDIOPATHIC PULMONARY FIBROSIS</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701740</gtr:grantReference><gtr:abstractText>Idiopathic pulmonary fibrosis (IPF) affects some 4000 people a year in the UK. There is no effective therapy and the average survival is 3 years. This means that IPF has a worse prognosis than many common cancers. We do not know what causes the disease, but inflammation is part of the complex disease process. The neutrophil is an inflammatory blood cell present in excess amounts in the lungs of patients with IPF. Normally, neutrophils only live for a few hours before dying and being removed by ?clearing? cells. In some diseases such as IPF, we believe that the neutrophil is able to survive longer in the lung, thereby injuring tissue and cause scarring. Corticosteroids are powerful anti-inflammatory drugs that are often used, but appear to not work well in IPF. 

Over the last 20 years, our group have studied how neutrophils are able to survive longer and crucially how we might overcome this to allow normal healing. We have now discovered that R-roscovitine, a drug that affects the cell survival, has the unique property of forcing activated neutrophils to die therefore preventing lung damage. R-roscovitine has been used recently in patients with cancers, since it may also be effective at killing tumour cells. These cancer studies show that the drug is safe to use in humans. We wish to perform a study of R-roscovitine in patients with IPF. We will firstly determine the optimum oral dose and side-effect profile in 20 patients with IPF. Next, we will perform a study in 40 patients with IPF randomly allocated receive a combination of R-roscovitine, no specific treatment or corticosteroids. We will measure neutrophils in lung fluid via bronchoscopy (a telescope into the lungs). We will also employ a non-invasive technique for measuring lung inflammation, the PET scan, which is able to detect neutrophils in the lung using X-rays.

Here in Edinburgh we have a constellation of facilities to ensure this study can be performed effectively and safely. Our large specialist clinic in which we see patients with IPF is within the same building as a Clinical Trials Facility with expertise in running trials of this nature. Adjacent to the main hospital is a state-of-the-art Research Institute in which the key discoveries of neutrophil survival and R-roscovitine properties were made, and which will house a PET scanning machine. These studies should provide the foundations for future definitive trials of R-roscovitine in IPF.</gtr:abstractText><gtr:technicalSummary>Idiopathic pulmonary fibrosis (IPF) is a disease of progressive scarring of the lung with a median survival time from diagnosis of just 3 years, a poorer prognosis than for cancer of the breast, colon or ovary. There are 4000 new cases of IPF diagnosed annually and in the absence of a proven effective treatment, novel therapies are urgently required. Furthermore, there is a need to identify biomarkers of disease activity and progression. Although there are contentious theories regarding the pathogenesis of IPF, there is ample evidence that persistent inflammation is an important component of disease pathogenesis. Our group has generated a unifying body of supportive evidence to show that normal inflammatory resolution is dependent upon neutrophil apoptosis, a process that is delayed an inflammatory milieu in situ; corticosteroids rather than overcoming inflammation-enhanced survival, actually retard neutrophil apoptosis. We have now identified that the CDK-inhibitor R-roscovitine exhibits the as yet unique property of over-riding pro-survival inflammatory signals and driving neutrophil apoptosis. We have shown in vivo that R-roscovitine promotes neutrophil apoptosis, enhances resolution of inflammation and attenuates lung injury in the bleomycin model of lung fibrosis. 
Early human studies of R-roscovitine have demonstrated its safety in patients with cancer, and here we propose a novel experimental medicine study of R-roscovitine in patients with IPF. We will firstly undertake a phase 1 study to establish the pharmacokinetics, safety and suitable dosing regime of oral R-roscovitine in prevalent cases of IPF. Guided by data from this study, we propose a small (n=40) factorial design phase 2 study to determine the efficacy of R-roscovitine in reducing lung neutrophil burden in incident patients with IPF. The primary end-point of the phase 2 study will be a neutrophil apoptotic index in bronchoalveolar lavage fluid. Furthermore consistent with the premise that these are experimental medicine studies, we will employ 18F-FDG PET, a marker of neutrophil activity, in this study with a view to qualifying this modality as a novel non-invasive biomarker in IPF.
In Edinburgh we have built a research team possessing considerable expertise in inflammatory cell biology, the mechanisms of inflammatory/scarring processes in human diseases and their experimental models, and the design and execution of clinical trials. This translational study is based on our original discovery of the previously unsuspected pro-resolution properties of R-roscovitine, and will be carried out in our established Interstitial Lung Disease Clinic under the auspices of the Wellcome Trust Clinical Research Facility.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>249991</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>University of Sheffield, UK. Lecture in honour of Prof Moira Whyte</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3C4382F0-7F35-433B-AF1E-8E20A53F0F4C</gtr:id><gtr:impact>University of Sheffield, UK. Lecture in honour of Prof Moira Whyte 'Modulation Of Inflammation Resolution &amp;amp; Apoptosis' June 25th 2014.</gtr:impact><gtr:outcomeId>58c59dbd302c89.93781703</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Milan, Resolution of Inflammation in Pulmonary Diseases , 24th March 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>806B396F-34B4-4339-852C-EE6B882EFC6E</gtr:id><gtr:impact>University of Milan, Resolution of Inflammation in Pulmonary Diseases , 24th March 2015</gtr:impact><gtr:outcomeId>58c59f9216c3f7.99578709</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	British Society for Immunology Inflammation Affinity Group, in conjunction with the Manchester Immunology Group. Manchester at the &quot;Inflammation and Disease&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D13E6D0B-508E-495A-92C6-996D9162B730</gtr:id><gtr:impact>British Society for Immunology Inflammation Affinity Group, in conjunction with the Manchester Immunology Group. Manchester at the &amp;quot;Inflammation and Disease&amp;quot; conference on 9th -10th of September, 2014.</gtr:impact><gtr:outcomeId>58c59e7f765147.70467340</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Edinburgh, Edinburgh-Zhejiang Joint Symposium 2014. Resolving lung inflammation,</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3611E4D8-3A56-4A3E-8BE8-BFCDC5B7F38E</gtr:id><gtr:impact>University of Edinburgh, Edinburgh-Zhejiang Joint Symposium 2014. Resolving lung inflammation, 3rd Sept 2014</gtr:impact><gtr:outcomeId>58c59e1b9cf173.94106979</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school visit, edinburgh</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>B00FBC9F-56DB-4CED-868C-39C9BE5E5969</gtr:id><gtr:impact>around 60 school children aged 7-11. their attention was captured by video images of englufing cells

there are plans to repeat this excercise</gtr:impact><gtr:outcomeId>kc1v3PKSZHj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>11th World Congress on Inflammation, Natal RN, Brazil, September, 21-25, 2013. Invited speaker &quot;Driving inflammatory cells apoptosis to resolve inflammation&quot;.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9809DA56-BA00-4CC7-8834-ED8C0BD5094D</gtr:id><gtr:impact>11th World Congress on Inflammation, Natal RN, Brazil, September, 21-25, 2013. Invited speaker &amp;quot;Driving inflammatory cells apoptosis to resolve inflammation&amp;quot;. Scheduled 24th Sept, 2013</gtr:impact><gtr:outcomeId>58c59b447da1d1.91312251</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCB, Slough, UK. &quot;Targeting neutrophil apoptosis to resolve lung inflammation&quot; 3rd November 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2161825D-83FB-45C8-9B20-BC5FCB8EE254</gtr:id><gtr:impact>UCB, Slough, UK. &amp;quot;Targeting neutrophil apoptosis to resolve lung inflammation&amp;quot; 3rd November 2016.</gtr:impact><gtr:outcomeId>58c5a397df6277.29405701</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>16th ANCA and Vasculitis Meeting, Paris,</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>03C522E5-2CAC-4E29-B3F9-063E4D05E2EB</gtr:id><gtr:impact>16th ANCA and Vasculitis Meeting, Paris, 14-17th April 2013. Plenary lecture entitled &amp;quot;Apoptosis, apoptotic cell clearance and resolution of inflammation&amp;quot;</gtr:impact><gtr:outcomeId>58c59a0c92dda3.23282032</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.sciencedirect.com/science/journal/07554982/42/4</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cardiff University, Cardiff School of Dentistry. &quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&quot;. 3rd March 2017.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>669DAFB7-9589-4E2E-9A08-902E3A220956</gtr:id><gtr:impact>Cardiff University, Cardiff School of Dentistry. &amp;quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&amp;quot;. 3rd March 2017.</gtr:impact><gtr:outcomeId>58c5a474b6ebf8.54696341</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>R&amp;D Systems Symposium &quot;The Role of Cytokines and Signalling in Inflammation&quot;.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7B765E82-6D9D-434C-9343-F6F94D6B92EF</gtr:id><gtr:impact>R&amp;amp;D Systems Symposium &amp;quot;The Role of Cytokines and Signalling in Inflammation&amp;quot;. Research Centre CAESAR, Ludwig-Erhard-Allee 2, 53175 Bonn. 15th October 2013.</gtr:impact><gtr:outcomeId>58c59bb57f4ac9.27519375</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	Edinburgh, SCRM. &quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&quot; Wellcome Trust Site Visit, 5th August, 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F95201CB-8150-46C4-A6C8-2BB4B38E295F</gtr:id><gtr:impact>Edinburgh, SCRM. &amp;quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&amp;quot; Wellcome Trust Site Visit, 5th August, 2016</gtr:impact><gtr:outcomeId>58c5a27762fbd0.73232820</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Aberdeen, Scottish Society of Cytomics SCC 2014.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C42C721B-8273-4EDF-A05C-C6BAA3878D34</gtr:id><gtr:impact>University of Aberdeen, Scottish Society of Cytomics SCC 2014. &amp;quot;Flow cytometric techniques for isolating and analysing leucocytes&amp;quot; 25-26th Sept 2014.</gtr:impact><gtr:outcomeId>58c59ede2f9599.38559568</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heriot-Watt University, School of Life Science, Edinburgh, UK. &quot;Strategies for enhancing the resolution of inflammation&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A7AEB5D9-67EA-4BC6-B77A-05190C4E5A87</gtr:id><gtr:impact>Heriot-Watt University, School of Life Science, Edinburgh, UK. &amp;quot;Strategies for enhancing the resolution of inflammation&amp;quot; 25th November, 2015</gtr:impact><gtr:outcomeId>58c5a1bb9bdf14.20187173</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	ESCCA 2016, Edinburgh, UK. &quot;Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells: strategies for enhancing the resolution of inflammation. - A 'festival of cell analysis, apoptosis and inflammation' (11-14th September, 2016). Talk on the 14th September 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C430A9F-C589-43B6-A95E-44AF0B4C5A19</gtr:id><gtr:impact>ESCCA 2016, Edinburgh, UK. &amp;quot;Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells: strategies for enhancing the resolution of inflammation. - A 'festival of cell analysis, apoptosis and inflammation' (11-14th September, 2016). Talk on the 14th September 2016.</gtr:impact><gtr:outcomeId>58c5a2b9ed74d1.01781705</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature Reviews Immunology. Resolving Inflammation conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E95DBE3D-8407-44B6-9BA2-B75E08F99EEC</gtr:id><gtr:impact>Nature Reviews Immunology. Resolving Inflammation: Mechanisms and Drug Discovery, Keble College, Oxford, UK. April 1-3, 2012. Talk entitled &amp;quot;Targeting inflammatory cell apoptosis to resolve inflammation&amp;quot;. Invited speaker in plenary session.

URL- http://www.nature.com/content/conferences/23393-02.html?WT.i_dcsvid=%%LIST_ID%%-%%RECIPIENT_ID%%&amp;amp;WT.ec_id=MARKETING</gtr:impact><gtr:outcomeId>58c5977c8abdf3.45724082</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Edinburgh. Edinburgh Infectious Disease Conference &quot;Resolution of Inflammation: Implications for Infectious Diseases&quot; 20th May 2015.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2B144989-9001-4408-BA86-A10482903D7E</gtr:id><gtr:impact>University of Edinburgh. Edinburgh Infectious Disease Conference &amp;quot;Resolution of Inflammation: Implications for Infectious Diseases&amp;quot; 20th May 2015.</gtr:impact><gtr:outcomeId>58c5a09ece06d0.39826299</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>THE PETER E. DRESEL MEMORIAL LECTURE IN PHARMACOLOGY 31st March 2015, Halifax, Canada. March</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>36D002AE-E330-49E7-BB2F-11EC873E0AAA</gtr:id><gtr:impact>THE PETER E. DRESEL MEMORIAL LECTURE IN PHARMACOLOGY 31st March 2015, Halifax, Canada. March. This was a prestigious yearly award in honour of Prof Dresel,</gtr:impact><gtr:outcomeId>58c5a02eac0265.04728135</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Edinburgh. QMRI, Public lecture &quot;Treating injured lungs by extinguishing inflammation&quot;. Feb 11th 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>93FCC832-DDF5-4BE2-81FF-538613C8E246</gtr:id><gtr:impact>University of Edinburgh. QMRI, Public lecture &amp;quot;Treating injured lungs by extinguishing inflammation&amp;quot;. Feb 11th 2015</gtr:impact><gtr:outcomeId>58c59f2fd54a21.05722662</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	Charles Darwin House, London, UK. Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells. Advances in Cytometry 2015. The Terry Hoy Lecture,</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5E406746-8B93-4FD2-9FF7-82997DA84D45</gtr:id><gtr:impact>Charles Darwin House, London, UK. Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells. Advances in Cytometry 2015. The Terry Hoy Lecture, 13th November 2015</gtr:impact><gtr:outcomeId>58c5a16e8f2c10.82900504</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>55th International Conference on the Bioscience of Lipids. Aberdeen, Scotland.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B329554B-AFD1-4294-8654-4D914EFE8D84</gtr:id><gtr:impact>55th International Conference on the Bioscience of Lipids. Aberdeen, Scotland. June 23-27th 2014. Invited speaker- plenary session.</gtr:impact><gtr:outcomeId>58c59d5273b650.62391870</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://conference.researchbib.com/view/event/36404</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Foz do Iguazu, Brazil. &quot;Pharmacological strategies to enhance the resolution of inflammation&quot; 48th Brazilian Congress of Pharmacology and Experimental Therapeutics and the 21st Latin American Congress of Pharmacology (47th October 2016). Talk on the 6th October 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EDB93520-C688-478F-8BC0-EAE603AF2904</gtr:id><gtr:impact>Foz do Iguazu, Brazil. &amp;quot;Pharmacological strategies to enhance the resolution of inflammation&amp;quot; 48th Brazilian Congress of Pharmacology and Experimental Therapeutics and the 21st Latin American Congress of Pharmacology (47th October 2016). Talk on the 6th October 2016.</gtr:impact><gtr:outcomeId>58c5a34ddc5267.17730254</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.socesfar.es/index.php/our-services-4/our-services-5/our-services-9/250-48-brazilian-congress</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pharmacology, Toxicology and Therapeutics Seminar, University of Edinburgh</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D1A14EDD-7CA3-417C-B617-3652D977DB3E</gtr:id><gtr:impact>Pharmacology, Toxicology and Therapeutics Seminar, &amp;quot;Killing inflammatory cells to resolve inflammation&amp;quot; Monday 5th November 2012, University of Edinburgh, QMRI.</gtr:impact><gtr:outcomeId>58c5988e5a9920.34692489</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation &amp; Inflammation Disease Area, Basel, Switzerland.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9FE181EC-216F-4F6C-83FB-B24AFC659994</gtr:id><gtr:impact>Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation &amp;amp; Inflammation Disease Area, Basel, Switzerland. &amp;quot;Apoptosis, Efferocytosis and the Resolution of Inflammation&amp;quot;. 6th May 2014.</gtr:impact><gtr:outcomeId>58c59c762ed841.17477658</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Convegno su Nuove Prospettive in Chimica Farmaceutica (NPCF7), Savigliano, Italy,  29-31 May 2013. Keynote Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5F29243D-CAE9-408A-A0D4-249D07511B63</gtr:id><gtr:impact>Convegno su Nuove Prospettive in Chimica Farmaceutica (NPCF7), Savigliano, Italy, 29-31 May 2013. Keynote Lecture &amp;quot;An introduction to the initiation, propagation and resolution of inflammation: Targeting the resolution of inflammation by pharmacological intervention&amp;quot; 20 May, 2013</gtr:impact><gtr:outcomeId>58c59a911b53a2.93269616</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Goethe University, Translation Research Innovation- Pharma, Frankfurt. &quot;Resolution of Inflammation&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FF20E021-E518-4DEA-8A32-4AB031CDF14E</gtr:id><gtr:impact>Goethe University, Translation Research Innovation- Pharma, Frankfurt. &amp;quot;Resolution of Inflammation&amp;quot; 6th July 2015</gtr:impact><gtr:outcomeId>58c5a10cb193f3.84590673</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Banff Inflammation Workshop, Banff, Canada.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0EFD03A9-5F6E-41BB-9420-C94BE2071868</gtr:id><gtr:impact>The Banff Inflammation Workshop, Banff, Canada, (31 Jan - 3 Feb 2013). Invited speaker and plenary lecture '&amp;quot;Resolution solutions!&amp;quot;. 1st Feb 2013</gtr:impact><gtr:outcomeId>58c59953c65665.82949208</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.ucalgary.ca/irn/meeting/banff-inflammation-workshop-2013</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Banff, Canada 2017. &quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&quot;. 10th Biennial Banff Inflammation Workshop (26-29th January 2017). Talk on 27th January 2017.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>46B17FDA-F02E-4B14-B968-700E817520E9</gtr:id><gtr:impact>Banff, Canada 2017. &amp;quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&amp;quot;. 10th Biennial Banff Inflammation Workshop (26-29th January 2017). Talk on 27th January 2017.</gtr:impact><gtr:outcomeId>58c5a4176cb082.14760479</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.ucalgary.ca/biw2017/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IUPHAR, Edinburgh, 2016. &quot;Pharmacological strategies to enhance the resolution of inflammation. NC-IUPHAR and BPS Focused Meeting on the Guide to Immunopharmacology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0261424E-AC4A-4382-AC49-C058513ECAD4</gtr:id><gtr:impact>IUPHAR, Edinburgh, 2016. &amp;quot;Pharmacological strategies to enhance the resolution of inflammation. NC-IUPHAR and BPS Focused Meeting on the Guide to Immunopharmacology (9-10th April, 2016). Talk on the 9th April 2016.</gtr:impact><gtr:outcomeId>58c5a219c100d2.22686390</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chief Scientists Office, Scotland</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>6FB8DF49-2405-4BD4-9B07-8E32B23F6FBD</gtr:id><gtr:outcomeId>cSv2LvDUSTQ0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BLF Project Grant</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:id>F0A66519-34EC-401E-B5FF-6C8406809BFF</gtr:id><gtr:outcomeId>E0E69D456C80</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Serial serum samples and bronchoalveolar lavage samples form patients with interstitial lung disease, including IPF.</gtr:description><gtr:id>AC7E7EF0-7FD1-48DD-893F-77E711373163</gtr:id><gtr:impact>nil yet</gtr:impact><gtr:outcomeId>6500ED376BB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Scottish Interstitial Lung Disease (ScILD) Gene and blood biobank</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A database/registry for idiopathic pulmonary fibrosis in Scotland designed to aid recruitment to clinical trials</gtr:description><gtr:id>83E3DC96-93F3-41C5-9114-386B2D39A2AA</gtr:id><gtr:impact>The database has allowed other centres to recruit to IPF clinical trials that they may not otherwise have achieved.</gtr:impact><gtr:outcomeId>D04DA8E5CE9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Scottish Interstitial Lung Disease (ScILD) database</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>84EBCF62-ED47-48C7-9513-B7416E6C3D22</gtr:id><gtr:title>Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1abc409071bef4dd7a7a537e60551734"><gtr:id>1abc409071bef4dd7a7a537e60551734</gtr:id><gtr:otherNames>Alessandri AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>ahrj6deKwvR</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701740</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>